nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.05.2004 | Article

Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci

verfasst von: M. Bertin, A. Muller, X. Bertrand, C. Cornette, M. Thouverez, D. Talon

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 5/2004

Einloggen, um Zugang zu erhalten

Abstract

To investigate the relationship between glycopeptide use and decreased susceptibility to teicoplanin in coagulase-negative staphylococci (CNS) isolates, data on teicoplanin susceptibility and glycopeptide use from existing microbiology laboratory and pharmacy databases were collected for the period between July 2000 and March 2001. Pooled data for the entire study period were first used to analyse associations. Univariate analysis showed that the incidence of CNS with decreased susceptibility to teicoplanin was significantly correlated with the use of glycopetides, particularly with vancomycin use. This association was confirmed by multivariate analysis. This study suggests that variations in antimicrobial resistance are related to variations in antimicrobial use in the model of CNS with decreased susceptibility to teicoplanin, thus confirming the usefulness of restricting antimicrobial prescribing as a means of controlling resistance.

Archer GL (1990) Staphylococcus epidermidis and other coagulase-negative staphylococci. In: Mandell GL, Douglas RG, Bennett JE (eds) Principles and practice of infectious diseases, 3rd edn. Churchill Livingstone, New York, pp 1511–1518

Pfaller MA, Herwaldt LA (1988) Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci. Clin Microbiol Rev 1:281–299PubMed

Archer GL, Climo MW (1994) Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 38:2231–2237PubMed

Karchmer AW, Archer GL, Dismukes WE (1983) Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 98:447–455

Grant AC, Lacey RW, Brownjohn AM, Turney JH (1986) Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 2:1166–1167CrossRefPubMed

Goldstein FW, Coutrot A, Sieffer A, Acar JF (1990) Percentages and distribution of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 34:899–900PubMed

Wilson AP, O’Hare MD, Felmingham D, Grüneberg RN (1986) Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 2:973CrossRefPubMed

Murphy OM, Stewart D, Gray J, Bint AJ (1996) Susceptibility of staphylococci to teicoplanin and vancomycin. J Antimicrob Chemother 38:316–317PubMed

McGowan JE Jr (1983) Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 5:1033–1048PubMed

10.

Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ (1996) Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. J Am Med Assoc 275:234–240CrossRef

11.

Lang S, Livesley MA, Lambert PA, Elliott J, Elliott TS (1999) The genomic diversity of coagulase-negative staphylococci associated with nosocomial infections. J Hosp Infect 43:187–193PubMed

12.

Tacconelli E, Tumbarello M, de Gaetano Donati K, Bettio M, Spanu T, Leone F, Sechi LA, Zanetti S, Fadda G, Cauda R (2001) Glycopeptide resistance among coagulase-negative staphylococci and clinical findings from a case-control study. Clin Infect Dis 33:1628–1635PubMed

13.

Soussy CJ, Carret G, Cavallo JD (2000) Antibiogram Committee of the French Microbiology Society. Report 2000–2001. Pathol Biol 48:832–871PubMed

14.

Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW (1998) Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis 17:20–24PubMed

15.

Lesch CA, Itokasu GS, Danziger LH, Weinstein RA (2001) Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 41:149–154CrossRefPubMed

16.

Lallemand S, Thouverez M, Boisson K, Talon D, Bertrand X (2002) Bacteremia caused by coagulase-negative staphylococci exhibiting decreased susceptibility to teicoplanin. J Hosp Infect 51:207–214CrossRefPubMed

17.

Boisson K, Bertin M, Thouverez M, Talon D, Bertrand X (2002) Characterisation of coagulase-negative staphylococci isolated from blood infections: incidence, susceptibility to glycopeptides and molecular epidemiology. Eur J Clin Microbiol Infect Dis 21:660–665CrossRefPubMed

18.

Cercenado E, Garcia-Leoni ME, Diaz MD, Sanchez-Carrillo C, Catalan P, De Quiros JC, Bouza E (1996) Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol 34:1765–1768PubMed

19.

Del’Alamo L, Cereda RF, Tosin I, Miranda EA, Sader HF (1999) Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. Diagn Microbiol Infect Dis 34:185–191PubMed

20.

White RL, Friedrich LV, Mihm LB, Bosso JA (2000) Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas. Clin Infect Dis 31:16–23CrossRefPubMed

21.

Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH (1978) Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC International Antimicrobial Therapy Project Group. J Infect Dis 137:14–29PubMed

22.

Lopez-Lozano JM, Monnet DL, Yague A, Burgos A, Gonzalo N, Campillos P, Saez M (2000) Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents 14:21–31CrossRefPubMed

23.

Monnet DL, Lopez-Lozano JM, Campillos P, Burgos A, Yague A, Gonzalo N (2001) Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models. Clin Microbiol Infect 7(Suppl 7):S29–S36CrossRef

24.

Spanik S, Trupl J, Studena M, Kremery V (1997) Breakthrough nosocomial bacteraemia due to teicoplanin-resistant Staphylococcus haemolyticus in five patients with acute leukaemia. J Hosp Infect 35:155–159PubMed

25.

Sloos JH, van de Klundert JAM, Dijkshoorn L, van Boven CPA (1998) Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital. J Antimicrob Chemother 42:787–791

26.

Biavasco F, Giovanetti E, Montanari MP, Lupidi R, Varaldo PE (1991) Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother 27:71–79PubMed

27.

28.

Wong SSY, Ho PL, Woo PCY, Yuen KY (1999) Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 29:760–767PubMed

29.

Monnet DL, Archibald LK, Phillips L, Tenover FC, McGowan JE Jr, Gaynes RP, the Intensive Care Antimicrobial Resistance Epidemiology Project and the National Nosocomial Infections Surveillance System Hospitals (1998) Antimicrobial use and resistance in eight U.S. hospitals: complexities of analysis and modelling. Infect Control Hosp Epidemiol 19:388–394PubMed

30.

Crowcroft NS, Ronveaux O, Monnet DL, Mertens R (1999) Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 20:31–36PubMed

Titel: Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci
verfasst von: M. Bertin
A. Muller
X. Bertrand
C. Cornette
M. Thouverez
D. Talon
Publikationsdatum: 01.05.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 5/2004
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-004-1129-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2004

May 2004

In Vitro Activity of the Active Metabolite of Prulifloxacin (AF 3013) Compared with Six Other Fluoroquinolones

Blastocystis hominis as a cause of hypoalbuminemia and anasarca

Plasma interleukin-6 levels in Mediterranean spotted fever

Rapid detection of Mycoplasma pneumoniae IgM antibodies in pediatric patients using ImmunoCard Mycoplasma compared to conventional enzyme immunoassays